SecBot SecBot
S-3 ·Filed May 12, 2026

PROF

Profound Medical Corp.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001104659-26-059487
Shelf registration, potential dilution
Actionable Insight • Neutral

This is a routine resale registration for existing shareholders from a prior private placement, not a new equity raise. The selling pressure is limited to 2.5% of shares outstanding, and the company's strong Q1 results and $50.3M cash position suggest no near-term capital need. Monitor for any subsequent prospectus supplement that could indicate a new primary offering.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.10
T+0 close · May 12, 2026 · via day close
Latest settled
+4.37%
T+60 · $7.41
Vs SPY
−0.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $7.10entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $7.10
  3. T+5 · 6mo ago −5.21%α −4.05% · $6.73
  4. T+20 · 5mo ago −6.34%α −5.73% · $6.65
  5. T+60 · 3mo ago +4.37%α −0.07% · $7.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical filed an S-3 registration statement to register 921,428 common shares for resale by selling shareholders who acquired them in a December 2025 private placement at $7.00/share. The company is not selling any shares or receiving proceeds from this filing. This is a routine resale registration for existing shareholders, not a new capital raise, and follows strong Q1 2026 results with 104% revenue growth and improved operating performance.

Key Financial Metrics

Dilution
2.5%

Key Facts

  • S-3 registers 921,428 common shares for resale by selling shareholders from a December 2025 private placement
  • Shares were issued at $7.00 per share for aggregate gross proceeds of approximately $6.45 million
  • Company will not receive any proceeds from the resale of shares under this prospectus
  • Filing follows Q1 2026 earnings (May 7) showing 104% revenue growth to $5.3M and net loss improvement of 34% to $0.19/share
  • Company had $50.3M cash as of March 31, 2026, with $59.4M in shareholders' equity
  • Selling shareholders include Fidelity True North Fund (300,000 shares) and funds associated with Timelo Investment Management (571,428 shares)
  • Registration covers approximately 2.5% of outstanding shares (36.3M shares outstanding as of May 7, 2026)

Financial Impact

No new capital raised; potential overhang of 921,428 shares (2.5% of outstanding) at ~$7.25/share market price, representing ~$6.7M in potential selling pressure

dilutionshare price

Risk Factors

  • Potential overhang from selling shareholders could create near-term downward pressure on stock price
  • Fidelity True North Fund and Timelo funds are significant holders; their selling could signal reduced conviction
  • Company remains pre-profitable with accumulated deficit of $294.8M and may need additional capital in the future

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001104659-26-059487
Document: tm2614107d1_ex-filingfees.htm0001104659-26-059487
Document: tm2614107d1_ex5-1.htm0001104659-26-059487
Document: tm2614107d1_ex23-1.htm0001104659-26-059487
Document: 0001104659-26-059487-index-headers.html0001104659-26-059487
Document: 0001104659-26-059487-index.html0001104659-26-059487
Document: 0001104659-26-059487.txt0001104659-26-059487

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026